Table 2.
Postoperative pathological characteristics and treatment.
| AdjC |
NAC |
|||
|---|---|---|---|---|
| N = 9000 | (%) | N = 5520 | (%) | |
| Invasive diameter | ||||
| 0 cm | 6 | 0.1 | 1020 | 18.5 |
| 0.1–2.0 cm | 4591 | 51.0 | 2253 | 40.8 |
| 2.1–5.0 cm | 3757 | 41.7 | 1081 | 19.6 |
| 5.1 cm- | 560 | 6.2 | 388 | 7.0 |
| Missing | 86 | 1.0 | 778 | 14.1 |
| Node metastases | ||||
| None | 6123 | 68.0 | 3869 | 70.1 |
| 1–3 nodes | 1887 | 21.0 | 947 | 17.2 |
| 4–9 nodes | 489 | 5.4 | 298 | 5.4 |
| 10 nodes or more | 289 | 3.2 | 139 | 2.5 |
| Missing | 212 | 2.4 | 267 | 4.8 |
| NG (postoperative) (y = 2013–2016) | ||||
| NG 1 | 594 | 6.6 | 496 | 9.0 |
| NG 2 | 1541 | 17.1 | 895 | 16.2 |
| NG 3 | 4520 | 50.2 | 1722 | 31.2 |
| Not tested or unknown | 447 | 5.0 | 1808 | 32.8 |
| Missing | 1898 | 21.1 | 599 | 10.9 |
| Margin (y = 2014–2016) | ||||
| Negative | 4855 | 53.9 | 3433 | 62.2 |
| Positive | 235 | 2.6 | 295 | 5.3 |
| Unknown | 200 | 2.2 | 102 | 1.8 |
| Missing | 3710 | 41.2 | 1690 | 30.6 |
| Breast surgery | ||||
| Bt | 4473 | 49.7 | 2596 | 47.0 |
| Bp | 4379 | 48.7 | 2825 | 51.2 |
| Others | 148 | 1.6 | 99 | 1.8 |
| Axillary surgery | ||||
| None | 215 | 2.4 | 231 | 4.2 |
| SN | 5399 | 60.0 | 2,129 | 38.6 |
| Ax | 3,197 | 35.5 | 3,013 | 54.6 |
| Sampling | 170 | 1.9 | 86 | 1.6 |
| Others or unknown | 19 | 0.2 | 61 | 1.1 |
| Chemotherapy | ||||
| Anthracyclin-taxane | 3794 | 42.2 | 4284 | 77.6 |
| Anthracycline | 2057 | 22.9 | 755 | 13.7 |
| Taxane | 2138 | 23.8 | 394 | 7.1 |
| Others | 1011 | 11.2 | 93 | 1.7 |
| Endocrine therapy | 682 | 7.6 | 591 | 10.7 |
| Radiotherapy | 3867 | 43.0 | 3457 | 62.6 |
NG = nuclear grade; Bt = total mastectomy; Bp = partial mastectomy; Ax = axillary lymph node dissection; SN = sentinel node biopsy.